Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Microcurrent Therapy and the Post-Exercise Physiological Response (MENS_PE) (MENS_PE)

9 novembre 2026 aggiornato da: University of Castilla-La Mancha

Microcurrent Therapy and the Post-Exercise Physiological Response: Effects on Creatine Kinase and Associations With Lactate.

The goal of this clinical trial is to find out whether microcurrent therapy changes blood levels of creatine kinase, a marker of muscle stress, during the first 48 hours after exercise in military personnel.

The main question is: Do creatine kinase levels after exercise differ between people who receive active microcurrent therapy and those who receive a sham treatment?

Twenty participants will complete a standardized exercise session. Participants will be randomly assigned to one of two groups: 10 will use an active microcurrent device, and 10 will use a sham device for the same period after exercise. The sham device looks and lights up like the active device but delivers no microcurrents.

Researchers will measure creatine kinase before exercise and 24 and 48 hours afterward, then compare how levels change in the two groups. Investigators will also measure blood lactate and perceived effort shortly after exercise, before either device is applied. Participants will report any difficulties using the device, discomfort, effects on sleep or rest, and unwanted effects.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Background and study design

Demanding physical exercise can cause physiological changes that persist after the activity has ended. Creatine kinase (CK) is an enzyme whose concentration in the blood can increase following muscle stress. This study will investigate whether prolonged transcutaneous microcurrent therapy after exercise changes the pattern of serum CK concentrations during the first 48 hours of recovery. The study will also characterize the immediate response to exercise and assess the practical use and tolerability of the intervention.

This is a randomized, controlled, parallel-group clinical trial involving 20 participants. Participants will be randomized in a 1:1 ratio to active microcurrent therapy or sham microcurrent therapy, with 10 participants in each group. All participants will complete the same standardized exercise protocol, and both groups will follow the same device application procedure. Participants will apply the devices to both legs for at least seven hours per day on each leg throughout the post-exercise treatment period.

The sham device has been modified so that its indicator light turns on in the same way as the active device, while it delivers no microcurrent output. Participants and outcome assessors will be blinded to group assignment. The personnel responsible for assessing outcomes will not be involved in assigning participants to groups.

Study objectives

Primary objective: To determine the effect of microcurrent therapy on the post-exercise serum creatine kinase response during the first 48 hours of recovery.

Secondary objectives:

Objective 1: To assess the feasibility and tolerability of microcurrent therapy, including difficulties with administration, adverse events, negative effects on sleep or rest.

Objective 2: To characterize the blood lactate response to the standardized exercise protocol and its short-term recovery during the first 30 minutes following exercise.

Objective 3: To characterize the change in perceived exertion immediately after exercise and during the first 30 minutes of recovery.

Objective 4: To assess the success of participant and assessor blinding.

Exploratory objectives:

Exploratory objective 1: To investigate the association between blood lactate concentrations after exercise and CK concentrations at 24 hours and 48 hours

Exploratory objective 2: To examine the relationship between post-exercise lactate concentration and subsequent CK concentration according to treatment allocation.

Exploratory objective 3: To investigate the association between early lactate recovery and early Rating of Perceived Exertion (RPE) recovery.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

20

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Toledo
      • Toledo, Toledo, Spagna, 45071
        • Campus de Toledo de la Universidad de Castilla-La Mancha (UCLM)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  • Age between 18 and 45 years.
  • Active-duty military personnel.
  • Healthy volunteers with current medical clearance.
  • Skin over the quadriceps free of lesions, burns, or irritation.
  • Availability and willingness to comply with the proposed intervention protocol.
  • Informed consent form read and signed.

Exclusion Criteria:

  • Implanted electronic devices: pacemakers, defibrillators, neurostimulators, etc.
  • Neuromuscular disease or peripheral neuropathy.
  • Treatment for HIV or chronic viral infections.
  • Uncontrolled seizure disorders (active epilepsy).
  • Uncontrolled, clinically significant heart disease.
  • Depression.
  • Uncontrolled hypertension.
  • Thrombosis.
  • Diabetes with neuropathy or impaired wound healing.
  • Active neoplasms or suspected cancer.
  • Recent musculoskeletal injuries (within the past three months) or chronic muscle pain in a lower limb.
  • Recent major surgery.
  • A dermatological condition in the quadriceps region.
  • Prescription of medications that may confound pain assessment during the seven days before or during the intervention, including nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and systemic corticosteroids.
  • Long-term treatment for hypercholesterolemia.
  • Prescription of antipsychotic or neuroleptic medications.
  • Long-term treatment for hypertriglyceridemia.
  • Alcohol or other substance abuse.
  • Inability to follow the intervention instructions.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Active Microcurrent Therapy

Participants randomized to the active microcurrent group will complete the standardized exercise protocol and the immediate and 30-minute post-exercise assessments before beginning treatment. Participants will then apply active transcutaneous microcurrent devices to both legs. Each leg will receive at least seven hours of device application per day throughout the post-exercise treatment period. The devices will deliver microcurrent output while in use. The study team will record any difficulties with application, adverse events, effects on sleep or rest, and perceived unpleasantness.

Prolonged post-exercise transcutaneous microcurrent therapy using an active microcurrent patch applied for minium 7 hours following exercise to promote recovery from exercise-induced muscle fatigue.

Comparatore fittizio: Sham Microcurrent Therapy

Participants randomized to the sham microcurrent group will complete the standardized exercise protocol and the immediate and 30-minute post-exercise assessments before beginning treatment. The participants will then apply sham devices to both legs. Each leg will receive at least seven hours of device application per day throughout the post-exercise treatment period.

The sham device is the same model as the active device, but it has been modified by an engineer. Its indicator light illuminates in the same way as the active device, while the microcurrent-generating function remains inactive and no microcurrent is delivered. The devices will otherwise be applied in exactly the same way in both groups, preserving participant and outcome-assessor blinding.

The study team will record any difficulties with application, adverse events, effects on sleep or rest, and perceived unpleasantness.

Prolonged post-exercise sham transcutaneous microcurrent intervention using a modified device engineered to reproduce the appearance and operating indicators of the active device, including illumination of the indicator light, while delivering no microcurrent output. The sham device is applied following the same procedure and for the same duration as the active intervention.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Serum creatine kinase (CK) concentration.
Lasso di tempo: Baseline, 24 hours, and 48 hours after exercise.

Unit: U/L.

Definition: Serum CK concentration will be measured at baseline and during the post- exercise recovery period at 24 and 48 hours. Baseline CK will be calculated as the mean of two measurements obtained one day before and on the day of the exercise protocol.

The primary analysis will evaluate whether the CK concentrations over time differs between the active microcurrent and sham groups.

Baseline, 24 hours, and 48 hours after exercise.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Participant-perceived feasibility of microcurrent treatment administration
Lasso di tempo: Immediately after the microcurrent treatment period.

Participants will report whether the intervention was easy to administer using a dichotomous response (Yes/No). The outcome will be summarized as the number and percentage of participants answering "Yes".

Immediately after the microcurrent treatment period.
Blood lactate concentration
Lasso di tempo: Pre-exercise, immediately post-exercise, and 30 minutes post-exercise.

Unit: mmol/L.

Definition: blood lactate concentration will be measured at baseline and inmediately post- exercise and at 30 min post-exercise.

The analysis will focus on changes over time during the first 30 minutes of recovery. The primary comparisons will concern the effect of time rather than the effect of treatment group, because all lactate measurements are obtained before microcurrent treatment. These measurements will be considered indicators of biochemical response to the exercise bout rather than measures of the effect of microcurrent therapy.

Pre-exercise, immediately post-exercise, and 30 minutes post-exercise.
Change in perceived exertion after exercise
Lasso di tempo: Immediately post-exercise and 30 minutes post-exercise.

Unit of Measure: Scale points from 0 to 10 Points

Description: Rating of perceived exertion will be assessed using the Borg Category-Ratio 10 Scale immediately after the standardized exercise protocol and 30 minutes later. The recorded score ranges from a minimum of 0 ("nothing at all") to a maximum of 10 ("extremely strong-maximal exertion"). Higher scores indicate greater perceived exertion, representing a less favorable outcome in terms of perceived exertion.

The change in perceived exertion will be calculated as the score at 30 minutes post-exercise minus the score immediately post-exercise. Possible change scores range from -10 to +10. Negative values indicate a reduction in perceived exertion, representing more favorable perceptual recovery; positive values indicate an increase, representing less favorable perceptual recovery.

Immediately post-exercise and 30 minutes post-exercise.
Participant and assessor blinding success
Lasso di tempo: Immediately after completion of the study intervention.

Unit: Categorical responses

Blinding success will be assessed by asking participants and outcome assessors to identify treatment allocation using five predefined response options: (1) strongly believe the treatment was active; (2) somewhat believe the treatment was active; (3) strongly believe the treatment was sham; (4) somewhat believe the treatment was sham; and (5) do not know

Immediately after completion of the study intervention.
Occurrence of adverse events
Lasso di tempo: Immediately after the microcurrent treatment period.

The occurrence of adverse events will be recorded as a yes/no response for each participant. The outcome will be reported as the number of participants experiencing at least one adverse event. The nature and characteristics of reported adverse events will also be documented descriptively.

Immediately after the microcurrent treatment period.
Negative effects on sleep or rest
Lasso di tempo: During and Immediately after the microcurrent treatment period.

Negative effects on sleep or rest during the microcurrent intervention will be assessed using participant-reported yes/no responses. The outcome will be reported as the number of participants reporting at least one negative effect on sleep or rest. The nature of reported effects will also be documented descriptively.

During and Immediately after the microcurrent treatment period.
Perceived unpleasantness of the microcurrent intervention
Lasso di tempo: Immediately after the microcurrent treatment period.

Unit of Measure: Numerical Rating Scale (NRS) score (1-10).

Description: Perceived unpleasantness of the microcurrent intervention will be assessed using a 11-point Numerical Rating Scale (NRS), ranging from 0 ("not unpleasant at all") to 10 ("extremely unpleasant"). Higher scores indicate greater perceived unpleasantness

Immediately after the microcurrent treatment period.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Juan Avendaño-Coy, PhD, University of Castilla-La Mancha

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 ottobre 2026

Completamento primario (Effettivo)

1 novembre 2026

Completamento dello studio (Effettivo)

10 novembre 2026

Date di iscrizione allo studio

Primo inviato

30 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

9 ottobre 2026

Primo Inserito (Effettivo)

16 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • MENS_Post-Exercise

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

It is planned to make the anonymized datasets publicly available through the Zenodo repository.

Periodo di condivisione IPD

At the time of manuscript submission for publication, after completion of the study

Criteri di accesso alla condivisione IPD

The anonymized dataset will be openly accessible to the entire research community through the Zenodo repository, without the need for prior request or approval.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .